Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study will assess if the presence of immune system cells in and around the tumor impacts
tumor shrinkage in patients receiving neoadjuvant chemoimmunotherapy for triple-negative
breast cancer.